ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30 | -98.1% | 295,200 | 0.0% | 0.00% | – |
| Q2 2023 | $1,567 | +4135.1% | 295,200 | -7.3% | 0.00% | -100.0% |
| Q1 2023 | $37 | +48.0% | 318,500 | +1066.7% | 0.01% | +100.0% |
| Q4 2022 | $25 | -100.0% | 27,300 | -24.8% | 0.00% | -70.0% |
| Q4 2021 | $384,000 | +36.7% | 36,300 | +14.9% | 0.01% | +11.1% |
| Q3 2021 | $281,000 | +71.3% | 31,600 | +89.2% | 0.01% | +80.0% |
| Q2 2021 | $164,000 | +51.9% | 16,700 | +10.6% | 0.01% | -16.7% |
| Q1 2021 | $108,000 | +163.4% | 15,100 | -34.9% | 0.01% | +50.0% |
| Q1 2019 | $41,000 | +412.5% | 23,200 | -87.1% | 0.00% | +300.0% |
| Q4 2018 | $8,000 | -97.8% | 180,500 | -14.4% | 0.00% | -95.7% |
| Q3 2018 | $366,000 | -63.6% | 210,800 | +5.7% | 0.02% | -54.0% |
| Q2 2018 | $1,005,000 | +415.4% | 199,397 | +14.5% | 0.05% | +400.0% |
| Q1 2018 | $195,000 | +323.9% | 174,100 | +187.8% | 0.01% | +233.3% |
| Q1 2017 | $46,000 | – | 60,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |